Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Summit Technology gets FDA approval for photorefractive keratectomy (PRK) laser

This article was originally published in Clinica

Executive Summary

Summit Technology has received US FDA approval for its excimer laser for treating photorefractive keratectomy. Summit, which is the first and only company to receive approval for its laser system for correcting short-sightedness, was notified that the product was approvable in September (see Clinica 673, p 17). PRK treatment involves the use of the laser to deliver pulses of ultraviolet light to remove thin layers from the corneal surface. Summit's laser system was approved for phototherapeutic keratectomy last March.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT093836

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel